Tetrahydroisoquinoline derivative

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8962612
APP PUB NO 20130317010A1
SERIAL NO

13956924

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

To provide an excellent agent for preventing or treating dementia and schizophrenia based on serotonin 5-HT5A receptor regulating action, it was found that a tetrahydroisoquinoline derivative characterized by a structure in which an acylguanidino group binds to a N atom of a tetrahydroisoquinoline ring or the like, and a cyclic group binds to an unsaturated ring has a potent 5-HT5A receptor regulating action and an excellent pharmacological action based on the regulating action and also discovered that the tetrahydroisoquinoline derivative is useful as an agent for treating or preventing dementia, schizophrenia, and the like, whereby the present invention has been completed.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ASTELLAS PHARMA INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Hamaguchi, Wataru Tokyo, JP 13 95
Kaneko, Osamu Tokyo, JP 16 150
Kinoyama, Isao Tokyo, JP 16 126
Koganemaru, Yohei Tokyo, JP 8 34
Miyazaki, Takehiro Tokyo, JP 7 20
Sekioka, Ryuichi Tokyo, JP 3 2
Washio, Takuya Tokyo, JP 11 16

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 24, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00